Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene JAK2
Variant R867Q
Impact List missense
Protein Effect gain of function
Gene Variant Descriptions JAK2 R867Q lies within the protein kinase domain 2 of the Jak2 protein (UniProt.org). R867Q results in constitutive activation of STAT3/5, AKT and ERK signaling, and increased proliferation in thrombopoietin receptor-expressing cells in culture (PMID: 24398328).
Associated Drug Resistance
Category Variants Paths

JAK2 mutant JAK2 act mut JAK2 R867Q

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_004972.4
gDNA chr9:g.5089702G>A
cDNA c.2600G>A
Protein p.R867Q
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_001322194 chr9:g.5089702G>A c.2600G>A p.R867Q RefSeq GRCh38/hg38
NM_004972.3 chr9:g.5089702G>A c.2600G>A p.R867Q RefSeq GRCh38/hg38
NM_001322195.1 chr9:g.5089702G>A c.2600G>A p.R867Q RefSeq GRCh38/hg38
NM_004972.4 chr9:g.5089702G>A c.2600G>A p.R867Q RefSeq GRCh38/hg38
NM_001322195.2 chr9:g.5089702G>A c.2600G>A p.R867Q RefSeq GRCh38/hg38
NM_001322196.2 chr9:g.5089702G>A c.2600G>A p.R867Q RefSeq GRCh38/hg38
NM_001322196 chr9:g.5089702G>A c.2600G>A p.R867Q RefSeq GRCh38/hg38
NM_001322195 chr9:g.5089702G>A c.2600G>A p.R867Q RefSeq GRCh38/hg38
NM_001322194.2 chr9:g.5089702G>A c.2600G>A p.R867Q RefSeq GRCh38/hg38
NM_004972 chr9:g.5089702G>A c.2600G>A p.R867Q RefSeq GRCh38/hg38
NM_001322194.1 chr9:g.5089702G>A c.2600G>A p.R867Q RefSeq GRCh38/hg38
NM_001322196.1 chr9:g.5089702G>A c.2600G>A p.R867Q RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
JAK2 R867Q hematologic cancer decreased response Luminespib Preclinical Actionable In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Luminespib (AUY922) in culture (PMID: 24398328). 24398328
JAK2 R867Q hematologic cancer decreased response Momelotinib Preclinical Actionable In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Momelotinib (CYT387) in culture (PMID: 24398328). 24398328
JAK2 R867Q hematologic cancer decreased response Ruxolitinib Preclinical Actionable In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Jakafi (ruxolitinib) in culture (PMID: 24398328). 24398328
JAK2 R867Q hematologic cancer decreased response Fedratinib Preclinical - Cell culture Actionable In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Inrebic (fedratinib) in culture (PMID: 24398328). 24398328
JAK2 R867Q hematologic cancer decreased response AZ960 Preclinical Actionable In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to AZ960 in culture (PMID: 24398328). 24398328